DIABETES DRUG NOTES Diabetes is becoming more common in both older and younger generations and in keeping with this escalation in cases, there are an ever increasing number of drugs and drug classes that are suitable to treat hyperglycaemia. In a unique blend of diabetes practice, clinical pharmacology, and cardiovascular medicine, Diabetes Drug Notes describes the principles of clinical pharmacology with regards to diabetes prescribing. Each drug class for the treatment of diabetes is covered in detail, along with the effect on the cardiovascular and renal systems caused by each drug.…mehr
Diabetes is becoming more common in both older and younger generations and in keeping with this escalation in cases, there are an ever increasing number of drugs and drug classes that are suitable to treat hyperglycaemia. In a unique blend of diabetes practice, clinical pharmacology, and cardiovascular medicine, Diabetes Drug Notes describes the principles of clinical pharmacology with regards to diabetes prescribing. Each drug class for the treatment of diabetes is covered in detail, along with the effect on the cardiovascular and renal systems caused by each drug. Building upon the success of their "Drug Notes" series for Practical Diabetes and their "Drugs for Diabetes" series in the British Journal of Cardiology, the team of experts focuses on the glycaemic management of type 1 and type 2 diabetes, with other effects of antidiabetic drugs covered as well.
Diabetes Drug Notes also includes: _ Comprehensive and up-to-date coverage of the drugs for the glycaemic management of patients with type 1 or type 2 diabetes _ Expert reflection on prescribing considerations for special groups, as well as common pitfalls in prescribing _ Detailed case histories to illustrate relevant information _ Summaries of recent guidelines related to diabetic intervention
Diabetes Drug Notes is a user-friendly guide for a general diabetes medical, nursing, and pharmacology readership, as well as those who support them.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Prof. Miles Fisher is a former Consultant Physician, Department of Diabetes, Endocrinology and Clinical Pharmacology, Glasgow Royal Infirmary, and an Honorary Professor at the University of Glasgow, UK. Prof. Gerard A. McKay is a Consultant Physician, Department of Diabetes, Endocrinology and Clinical Pharmacology, Glasgow Royal Infirmary, an Honorary Clinical Associate Professor, University of Glasgow, as well as a Visiting Professor at the University of Strathclyde, UK. Dr Andrea Llano is a Consultant Physician, Department of Diabetes, Endocrinology and Clinical Pharmacology, Glasgow Royal Infirmary, and an Honorary Clinical Lecturer, University of Glasgow, UK.
Inhaltsangabe
Foreword xx
Preface xxi
Editors and Contributors xxii
Introduction 1
1 Clinical Pharmacology of Antidiabetic Drugs 2 Andrea Llano, Gerry McKay, and Ken Paterson
Introduction 2
Clinical Pharmacology 3
Drug Metabolism and Elimination 6
Drug Development and Clinical Trials 7
Drug Licensing of Antidiabetic Drugs 12
Development and Licensing of Insulin 14
Development and Approval of Biosimilar Insulin 16
Pharmacovigilance 19
Pharmacoeconomics 21
Future Developments in Diabetes Clinical Pharmacology 26
2 Metformin 30 Joseph Timmons and James Boyle
Introduction 30
Pharmacology 32
Mechanism of Action 32
Glycaemic Efficacy 36
Safety and Side Effects 37
Metformin in Type 1 Diabetes 45
Place of Metformin in Current and Future Practice 46
3 Sulfonylureas and Meglitinides 49 Joseph Timmons and James Boyle
Introduction 49
Pharmacology 51
Glycaemic Efficacy 53
Safety and Side Effects 55
Outcome Trials 56
Meglitinides 61
Place of Sulfonylureas and Meglitinides in Current and Future Practice 65
4 DPP-4 Inhibitors 67 Sharon Mackin and Gemma Currie
Introduction 67
Pharmacology 68
Glycaemic Efficacy 75
Safety and Side Effects 79
Outcome Trials 82
Renal Outcomes 89
The Place of DPP-4 Inhibitors in Current and Future Practice 91
5 SGLT2 Inhibitors 95 Miles Fisher, Andrea Llano, and Gerry McKay
Introduction 96
Pharmacology 96
Glycaemic Efficacy 100
Side Effects and Safety 103
Outcome Trials 105
Renal Outcome Trials 110
Heart Failure Outcome Trials 116
SGLT2 Inhibitors in Type 1 Diabetes 119
Use of SGLT2 Inhibitors in Other Diseases 123
Dare- 19 123
Place of SGLT2 Inhibitors in Current and Future Practice 124
6 GLP-1 Receptor Agonists 130 Catherine Russell and John Petrie
Introduction 130
Pharmacology 131
Glycaemic Efficacy and Effect on Weight 137
Side Effects and Safety 142
Outcome Trials 143
Use of GLP-1 Receptor Agonists in Other Diseases 153
Place of GLP-1 Receptor Agonists in Current and Future Practice 155
7 Animal and Human Insulins 161 Ken Paterson
Introduction 161
Production and Pharmacokinetic Modifications 165
Hypoglycaemia and Human Insulin 170
Intensified Insulin Therapy 173
Place of Human Insulin in Current and Future Therapy 176
8 Short-acting Insulin Analogues 179 Kate Hughes and Gerry McKay
Introduction 179
Factors Affecting Absorption and Metabolism of Short-acting Insulin 180
